TBD
The Royal Society of Medicine
London, UK
Registration for this free networking event is now live.
TBD
The Royal Society of Medicine
London, UK
Registration for this free networking event is now live.
Join SLAS and ELRIG in an extraordinary collaboration showcasing the latest pharmaceutical innovations. From revolutionary mRNA technologies to cutting-edge developments in antibodies and cell and gene therapies, immerse yourself in the dynamic evolution of drug discovery and therapeutics—experience the innovations setting the stage for a new era in medicine.
When: Tuesday, 3 December 2024
Where: The Royal Society of Medicine
Royal Society of Medicine
1 Wimpole Street
London
W1G 0AE
This event is a junction for industry leaders, researchers, and innovators to come together, share their groundbreaking ideas and delve into the transformative developments shaping the future of drug discovery and therapeutics. By highlighting the trailblazing innovations across new drug modalities and biologics, we aim to ignite collaboration, spark ingenuity and propel progress in the pharmaceutical sector.
| Tuesday, 3 December, 2024 | |
| 9:00 – 10:00 | Registration & Refreshments |
| 10:00 – 10:10 | Event Welcome & ELRIG/SLAS Intro |
| 1st Session | |
| 10:10 – 10:40 | Keynote Speaker + Q&A Chris Molloy (Medicines Discovery Catapult) Topic: Innovation and the discovery of new modality medicines - a view from MDC/UK |
| 10:40 – 11:10 | Networking Partner | TBA |
| 11:10 – 11:40 | Speaker + Q&A Lucy Edwardes Jones, M.Sc. (BGF) Topic: Innovation for new medicines from VC POV |
| 11:40 – 12:10 | Refreshment Break |
| 12:10 – 12:40 | Speaker + Q&A Johanna Huchting, Ph.D. (Fraunhofer ITMP ScreeningPort) Topic: Drugging Transformative Targets in Oncology with Molecular Glues |
| 12:40 – 12:45 | Vendor Talk | TBA |
| 12:45 – 13:15 | Speaker + Q&A Sigitas Mikutis, Ph.D. (University of Cambridge) Topic: TPD screening workflows and showcase performance through examples of targets that are well-known and advanced in the TPD field |
| 13:15 – 14:40 | Lunch Break |
| 2nd Session | |
| 14:40 – 15:10 | Speaker + Q&A TBA |
| 15:10 – 15:15 | Vendor Talk | TBA |
| 15:15 – 15:45 | Speaker + Q&A TBA |
| 15:45 – 15:50 | Vendor Talk | TBA |
| 15:50 – 16:20 | Innovation AveNEW Speakers |
| 16:20 – 16:30 | Closing Remarks |
| 16:30 – 18:00 | Networking Apero |
This event will feature a variety of speakers. Each session will last 30 minutes (20 minutes for presentation, 10 minutes for Q&A). Learn more about each of our speakers ahead of the networking forum.
Topic: Innovation and the discovery of new modality medicines - a view from MDC/UK
Chris Molloy has a 30-year international board and executive career across a unique range of life sciences R&D disciplines. He began in preclinical research at Glaxo and then held leadership roles at MerLion Pharmaceuticals, IDBS and the RSA Group. As the founding CEO of Medicines Discovery Catapult (MDC), he leads an experienced executive team and a cohort of over 130 specialists to achieve the organization's vision of reshaping drug discovery for patient benefit.
Lucy Edwardes Jones, M.Sc. (BGF)
Topic: Innovation for new medicines from VC POV
[BIO]
Johanna Huchting, Ph.D. (Fraunhofer ITMP ScreeningPort)
Topic: Drugging Transformative Targets in Oncology with Molecular Glues
[BIO]
Sigitas Mikutis, Ph.D. (University of Cambridge)
Topic: TPD screening workflows and showcase performance through examples of targets that are well-known and advanced in the TPD field
[BIO]
We are thrilled to provide the opportunity for drug discovery companies to connect directly with attendees and demonstrate their cutting-edge technologies. During each vendor talk, the presenting company will present a brief overview of its unique offerings.